| Autor: |
Domanović D; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Ushiro-Lumb I; National Transfusion Microbiology Reference Laboratory, NHS Blood and Transplant and Public Health England, London, England., Compernolle V; Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium., Brusin S; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Funk M; Pharmacovigilance II, Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines, Langen, Germany., Gallian P; Etablissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France., Georgsen J; South Danish Transfusion Service, Department of Clinical Immunology, Odense University Hospital, Odense, Denmark., Janssen M; Department of Donor Medicine Research, Transfusion Technology Assessment, Sanquin Research, Amsterdam, The Netherlands., Jimenez-Marco T; Balearic Islands Blood and Tissue Bank Foundation, Palma de Mallorca, Spain., Knutson F; Clinical Immunology and Transfusion Medicine IGP, Uppsala University, Uppsala, Sweden., Liumbruno GM; Italian National Blood Centre, National Institute of Health, Rome., Mali P; Blood Transfusion Center of Slovenia, Ljubljana, Slovenia., Marano G; Italian National Blood Centre, National Institute of Health, Rome., Maryuningsih Y; World Health Organization, Geneva, Switzerland., Niederhauser C; Interregional Blood Transfusion Swiss Red Cross, Laboratory Diagnostics, Bern, Switzerland., Politis C; Hellenic Coordinating Hemovigilance Center, Hellenic National Public Health Organization, Athens, Greece., Pupella S; Italian National Blood Centre, National Institute of Health, Rome., Rautmann G; European Directorate for the Quality of Medicines and HealthCare, Strasbourg, France., Saadat K; Austrian Agency for Health and Food Safety, Wien, Austria., Sandid I; French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France., Sousa AP; Portuguese Blood and Transplantation Center, Lisbon, Portugal., Vaglio S; Italian National Blood Centre, National Institute of Health, Rome., Velati C; Italian National Blood Centre, National Institute of Health, Rome., Verdun N; Office of Blood Research and Review, Center for Biologics Evaluation and Research, FDA, Silver Spring, United States of America., Vesga M; Basque Center for Transfusion and Human Tissues/Spanish Scientific Committee for Transfusion Safety, Galdakao, Spain., Rebulla P; IRCCS Foundation Ca' Granda Maggiore Policlinico Hospital, Milan, Italy. |
| Abstrakt: |
Pathogen reduction (PR) of selected blood components is a technology that has been adopted in practice in various ways. Although they offer great advantages in improving the safety of the blood supply, these technologies have limitations which hinder their broader use, e.g. increased costs. In this context, the European Centre for Disease Prevention and Control (ECDC), in co-operation with the Italian National Blood Centre, organised an expert consultation meeting to discuss the potential role of pathogen reduction technologies (PRT) as a blood safety intervention during outbreaks of infectious diseases for which (in most cases) laboratory screening of blood donations is not available. The meeting brought together 26 experts and representatives of national competent authorities for blood from thirteen European Union and European Economic Area (EU/EEA) Member States (MS), Switzerland, the World Health Organization, the European Directorate for the Quality of Medicines and Health Care of the Council of Europe, the US Food and Drug Administration, and the ECDC. During the meeting, the current use of PRTs in the EU/EEA MS and Switzerland was verified, with particular reference to emerging infectious diseases (see Appendix). In this article, we also present expert discussions and a common view on the potential use of PRT as a part of both preparedness and response to threats posed to blood safety by outbreaks of infectious disease. |
